- Senti Biosciences is a **logic-gated cell therapy company** developing treatments for acute myeloid leukemia (AML) and other blood cancers, with their lead program being **SENTI-202**.  **[1854270_2156125_0]** 
- **SENTI-202** is a first-in-class, off-the-shelf NK cell therapy for AML, which recently received **orphan drug designation**.  **[1854270_2156125_0]** **[1854270_2156125_1]** 
- The therapy is engineered with an **OR logic gate** to target CD33 and FLT3 on cancer cells (including leukemic stem cells) and a **NOT logic gate** (endomucin) to protect healthy hematopoietic stem cells.  **[1854270_2156125_1]** **[1854270_2156125_2]** 
- Preliminary efficacy data from the ongoing Phase 1 clinical trial showed **positive results**, with **two out of three patients in the recommended Phase 2 dose (RP2D) cohort achieving complete remission (CR) and being MRD negative**.  **[1854270_2156125_3]** 
- The trial demonstrated a **favorable safety profile** for SENTI-202, with no grade 3 or serious adverse events directly related to the therapy.  **[1854270_2156125_3]**

Senti Biosciences (SNTI)